FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2090925937> ?p ?o ?g. }

• W2090925937 endingPage "537" @default.
• W2090925937 startingPage "525" @default.
• W2090925937 abstract "Summarize safety and tolerability of duloxetine in treating diabetic peripheral neuropathic pain.Pooled data from three double-blind, randomized studies with 12-week, placebo-controlled (acute) and 52-week, routine-care-controlled (extension) phases.Frequency/discontinuations due to treatment-emergent adverse events (TEAEs).There were 1139 (placebo, n = 339; duloxetine, n = 800) and 867 (routine-care, n = 287; duloxetine, n = 580) patients in the acute and extension phases, respectively. Patient details were as follow: 60 years (mean age); Caucasian, 84%; and male, 57%. In the acute phase, there were significantly more TEAEs, duloxetine versus placebo (p = 0.001), the most common being nausea and somnolence. Discontinuations due to adverse events were significantly greater (12.5 vs 5.6%, p < 0.001), with similar outcomes in the extension phase. Baseline-to-endpoint aspartate transaminase/alanine transaminase were significantly increased and fasting plasma glucose was increased for duloxetine (0.67 mmol/l) versus decreased in routine-care (-0.64 mmol/l, p < 0.001). HbA1c was significantly increased, duloxetine vs routine-care, in the extension phase (52 vs 19%, p < 0.001). Endpoint measures neuropathy, nephropathy and retinopathy indicated no disease progression.Duloxetine was generally safe and well tolerated, with the three most commonly reported TEAEs being nausea, somnolence and constipation. Modest changes in glycemia were associated with duloxetine. Aspartate transaminase/alanine transaminase increases were transient and not considered predictive of more severe outcomes." @default.
• W2090925937 created "2016-06-24" @default.
• W2090925937 creator A5027240972 @default.
• W2090925937 creator A5048315541 @default.
• W2090925937 creator A5054710165 @default.
• W2090925937 creator A5057857378 @default.
• W2090925937 creator A5070346017 @default.
• W2090925937 creator A5088232571 @default.
• W2090925937 date "2010-05-14" @default.
• W2090925937 modified "2023-10-14" @default.
• W2090925937 title "Safety and tolerability of duloxetine in the acute management of diabetic peripheral neuropathic pain: analysis of pooled data from three placebo-controlled clinical trials" @default.
• W2090925937 cites W1970747203 @default.
• W2090925937 cites W1984259090 @default.
• W2090925937 cites W2003924139 @default.
• W2090925937 cites W2012561402 @default.
• W2090925937 cites W2016577926 @default.
• W2090925937 cites W2040163165 @default.
• W2090925937 cites W2043595892 @default.
• W2090925937 cites W2052512933 @default.
• W2090925937 cites W2070675447 @default.
• W2090925937 cites W2072534151 @default.
• W2090925937 cites W2072833030 @default.
• W2090925937 cites W2091122825 @default.
• W2090925937 cites W2092975953 @default.
• W2090925937 cites W2105305534 @default.
• W2090925937 cites W2106059433 @default.
• W2090925937 cites W2106807118 @default.
• W2090925937 cites W2112241702 @default.
• W2090925937 cites W2114613490 @default.
• W2090925937 cites W2135932738 @default.
• W2090925937 cites W2138512124 @default.
• W2090925937 cites W2146594973 @default.
• W2090925937 cites W2149813500 @default.
• W2090925937 cites W2153789216 @default.
• W2090925937 cites W2159609548 @default.
• W2090925937 cites W2160315861 @default.
• W2090925937 cites W2160816722 @default.
• W2090925937 cites W2236268895 @default.
• W2090925937 cites W2329242769 @default.
• W2090925937 cites W58909306 @default.
• W2090925937 cites W60025275 @default.
• W2090925937 doi "https://doi.org/10.1517/14740338.2010.484418" @default.
• W2090925937 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20465525" @default.
• W2090925937 hasPublicationYear "2010" @default.
• W2090925937 type Work @default.
• W2090925937 sameAs 2090925937 @default.
• W2090925937 citedByCount "19" @default.
• W2090925937 countsByYear W20909259372012 @default.
• W2090925937 countsByYear W20909259372013 @default.
• W2090925937 countsByYear W20909259372014 @default.
• W2090925937 countsByYear W20909259372015 @default.
• W2090925937 countsByYear W20909259372016 @default.
• W2090925937 countsByYear W20909259372018 @default.
• W2090925937 countsByYear W20909259372019 @default.
• W2090925937 countsByYear W20909259372021 @default.
• W2090925937 countsByYear W20909259372022 @default.
• W2090925937 countsByYear W20909259372023 @default.
• W2090925937 crossrefType "journal-article" @default.
• W2090925937 hasAuthorship W2090925937A5027240972 @default.
• W2090925937 hasAuthorship W2090925937A5048315541 @default.
• W2090925937 hasAuthorship W2090925937A5054710165 @default.
• W2090925937 hasAuthorship W2090925937A5057857378 @default.
• W2090925937 hasAuthorship W2090925937A5070346017 @default.
• W2090925937 hasAuthorship W2090925937A5088232571 @default.
• W2090925937 hasConcept C126322002 @default.
• W2090925937 hasConcept C142724271 @default.
• W2090925937 hasConcept C197934379 @default.
• W2090925937 hasConcept C203092338 @default.
• W2090925937 hasConcept C204787440 @default.
• W2090925937 hasConcept C27081682 @default.
• W2090925937 hasConcept C2778375690 @default.
• W2090925937 hasConcept C2779034229 @default.
• W2090925937 hasConcept C2780580376 @default.
• W2090925937 hasConcept C2780764818 @default.
• W2090925937 hasConcept C2910564767 @default.
• W2090925937 hasConcept C42219234 @default.
• W2090925937 hasConcept C535046627 @default.
• W2090925937 hasConcept C71924100 @default.
• W2090925937 hasConceptScore W2090925937C126322002 @default.
• W2090925937 hasConceptScore W2090925937C142724271 @default.
• W2090925937 hasConceptScore W2090925937C197934379 @default.
• W2090925937 hasConceptScore W2090925937C203092338 @default.
• W2090925937 hasConceptScore W2090925937C204787440 @default.
• W2090925937 hasConceptScore W2090925937C27081682 @default.
• W2090925937 hasConceptScore W2090925937C2778375690 @default.
• W2090925937 hasConceptScore W2090925937C2779034229 @default.
• W2090925937 hasConceptScore W2090925937C2780580376 @default.
• W2090925937 hasConceptScore W2090925937C2780764818 @default.
• W2090925937 hasConceptScore W2090925937C2910564767 @default.
• W2090925937 hasConceptScore W2090925937C42219234 @default.
• W2090925937 hasConceptScore W2090925937C535046627 @default.
• W2090925937 hasConceptScore W2090925937C71924100 @default.
• W2090925937 hasIssue "4" @default.
• W2090925937 hasLocation W20909259371 @default.
• W2090925937 hasLocation W20909259372 @default.
• W2090925937 hasOpenAccess W2090925937 @default.
• W2090925937 hasPrimaryLocation W20909259371 @default.
• W2090925937 hasRelatedWork W1990079987 @default.

• next